Quick Answer
Whitehawk Therapeutics, Inc. reported Research And Development Expense of $90.96 million for the year ending 2025.
- Whitehawk Therapeutics, Inc. showed an increase of +78.3% in Research And Development Expense from 2024 to 2025.
- This data is from Whitehawk Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $2.99 million | Q2 2016: $2.90 million | Q3 2016: $3.48 million | Q1 2017: $2.26 million | Q2 2017: $3.17 million | Q3 2017: $2.94 million | Q1 2018: $4.03 million | Q2 2018: $4.23 million | Q3 2018: $4.35 million | Q1 2019: $5.59 million | Q2 2019: $2.26 million | Q3 2019: $2.84 million | Q1 2020: $1.83 million | Q2 2020: $3.55 million | Q3 2020: $2.40 million | Q1 2021: $3.64 million | Q2 2021: $3.05 million | Q3 2021: $5.75 million | Q1 2022: $6.79 million | Q2 2022: $7.73 million | Q3 2022: $8.77 million | Q1 2023: $10.96 million | Q2 2023: $13.32 million | Q3 2023: $11.89 million | Q1 2024: $13.59 million | Q2 2024: $13.09 million | Q3 2024: $10.00 million | Q1 2025: $8.79 million | Q2 2025: $48.81 million | Q3 2025: $14.35 million.
- Over the full 10 years of available data (2016 to 2025), Whitehawk Therapeutics, Inc.'s Research And Development Expense has grown by 700.2%.
- Historical annual values: Fiscal year 2025: $90.96 million | Fiscal year 2024: $51.03 million | Fiscal year 2023: $48.93 million | Fiscal year 2022: $32.66 million | Fiscal year 2021: $19.67 million | Fiscal year 2020: $15.01 million | Fiscal year 2019: $12.82 million | Fiscal year 2018: $17.85 million | Fiscal year 2017: $12.15 million | Fiscal year 2016: $11.37 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: